Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6511750 | 0.89 | HDAC1 (0.65) | HDAC1HDAC8HDAC6BRPF1HDAC3 | |
| SCHEMBL1883615 | 0.88 | HDAC1 (0.83) | HDAC1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL8291893 | 0.88 | HDAC1 (0.65) | HDAC1MEN1MAPTKMT2AHDAC8 | |
| SCHEMBL1888015 | 0.82 | MAPT (0.77) | HDAC1MEN1MAPTKMT2AHDAC8 | |
| SCHEMBL6510207 | 0.81 | HDAC1 (0.55) | HDAC1MEN1MAPTKMT2AHDAC8 | |
| SCHEMBL1886482 | 0.79 | HDAC1 (1.00) | HDAC1 | |
| SCHEMBL6507545 | 0.79 | HDAC1 (0.60) | HDAC1MEN1MAPTKMT2AHDAC8 | |
| SCHEMBL5809799 | 0.79 | HDAC1 (0.67) | HDAC1MEN1MAPTKMT2A | |
| SCHEMBL6511964 | 0.76 | HDAC1 (0.76) | HDAC1MEN1MAPTKMT2AHDAC8 | |
| SCHEMBL17149302 | 0.76 | HDAC1 (0.76) | HDAC1MEN1KMT2AHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | claimed |
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137234-A1 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC11 | HDAC1 1/4885MEN1 2925/4885MAPT 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.